ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,969 | -44.3% | 2,819 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $26,865 | +39.1% | 2,819 | +60.5% | 0.00% | 0.0% |
| Q1 2023 | $19,316 | -47.1% | 1,756 | -28.8% | 0.00% | -50.0% |
| Q4 2022 | $36,497 | -22.6% | 2,466 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $47,125 | +3.9% | 2,466 | +15.8% | 0.00% | 0.0% |
| Q2 2022 | $45,369 | +38.2% | 2,129 | +24.9% | 0.00% | +100.0% |
| Q1 2022 | $32,838 | -79.9% | 1,705 | -78.3% | 0.00% | -50.0% |
| Q4 2021 | $163,328 | -13.2% | 7,875 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $188,134 | -12.5% | 7,875 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $214,909 | +31.2% | 7,875 | +39.1% | 0.00% | +50.0% |
| Q1 2021 | $163,744 | +2.8% | 5,660 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $159,216 | -4.0% | 5,660 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $165,838 | +45.2% | 5,660 | +49.9% | 0.00% | +50.0% |
| Q2 2020 | $114,216 | +1.5% | 3,777 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $112,555 | – | 3,777 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |